The company is a research-led and market-oriented biomedical company that has been operating in the Chinese pharmaceutical industry for over 25 years. The Group has an international perspective and is closely integrated with the solid infrastructure for drug development, clinical development, regulation, manufacturing, sales and marketing established in mainland China. The Group has established extensive cooperative relationships with more than 20 international companies, and currently promotes more than 25 kinds of patented, generic and imported pharmaceutical products in mainland China, Hong Kong, Macau, and Taiwan. The Group is committed to many important disease fields such as cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology and obstetrics. There are more than 40 types of products at various stages of development, from in-house research and development and from development, commercialization and production rights introduced from American, European and Japanese companies. The Group conducts sales and distribution activities in Hong Kong, China, Macau, Taiwan and mainland China through its Hong Kong and Taiwan offices and branches in Chongqing, Guangzhou, Shanghai and Beijing, covering most provinces and cities in mainland China, promoting domestic self-developed and imitation products and products imported from overseas. Zhaoke Hefei currently operates the Group's production plant in Hefei, Anhui Province, China. The plant has four GMP-compliant factories, which are responsible for the production of gels, freeze-dried powder injections for injection, small-volume injections and eye gels. Zhaoke Guangzhou is currently operating a pharmaceutical factory in Nansha District, Guangzhou, China (including a complete solid formulation production line for the development and production of tablets and capsules). The Group's mission is to become a successful biomedical group in Asia, providing innovative products to fight diseases, improve health and improve quality of life.
No Data